New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
09:14 EDTTGT, MNKD, FIVE, PSUN, YRCW, PUBGY, OMC, ICPT, ANF, AA, M, SHLD, BLDPOn The Fly: Pre-market Movers
HIGHER: Abercrombie & Fitch (ANF), up 15% after company raises FY adjusted EPS view, shares upgraded at Janney Capital. Macy's (M), up 1.2% after upgraded at Goldman... Intercept (ICPT), up 33.5% after price targets raised at Citigroup, BofA/Merrill and Oppenheimer... Omnicom (OMC), up 2% after Reuters reported EU clears merger with Publicis (PUBGY). LOWER: Target (TGT), down 1% after lowering Q4 comparable sales view, disclosing that information from up to 70M guests taken during data breach... Sears (SHLD), down 11% after saying fourth quarter sales-to-date are down 7.6% and projecting fourth quarter and fiscal-2013 losses that were larger-than-expected... Alcoa (AA), down 6.5% after earnings miss expectations... Pacific Sunwear (PSUN), down 18.4% after sales metrics, guidance, downgrade at Janney Capital... Five Below (FIVE), down 9.7% after cutting fourth quarter guidance... YRC Worldwide (YRCW), down 20% after the International Brotherhood of Teamsters announced that employees did not approve the memorandum of understanding extension proposal made by the company... MannKind (MNKD), down 11.6% after announcing tentative date of FDA advisory committee review of Afrezza.
News For TGT;SHLD;M;AA;ANF;ICPT;OMC;PUBGY;YRCW;PSUN;FIVE;MNKD;BLDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
09:23 EDTMCitigroup to hold a tour
Athletic Footwear Mall Tour travels to Roosevelt Field Mall, Garden City, New York on October 8.
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTAAFutures suggest a bounce at the open
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
06:16 EDTSHLDSears Holdings volatility elevated
Subscribe for More Information
05:53 EDTMNKDStocks with implied volatility movement; MNKD AFSI
Stocks with implied volatility movement; MannKind (MNKD) 85, AmTrust Financial (AFSI) 68 according to iVolatility.
October 7, 2014
15:13 EDTAAEarnings Preview: Alcoa sees Q3 EPS to 'continue to build on strong Q2'
Alcoa (AA) is scheduled to report third quarter earnings after the close on Wednesday, October 8, with a conference call scheduled for 5:00 pm ET. Alcoa is a global manufacturer of aluminum products. EXPECTATIONS: Analysts are looking for earnings per share of 23c on revenue of $5.85B, according to First Call. The consensus range for EPS is 15c-28c on revenue of $5.62B-$6.07B. LAST QUARTER: Alcoa reported second quarter adjusted EPS of 18c against estimates for 12c on revenue of $5.8B against estimates for $5.66B. The company reiterated its 2014 global aluminum demand growth view of 7%, and backed its 2014 global aerospace growth outlook of 8%-9%. It raised its 2014 estimate for the North America commercial transportation market to 10%-14%, from a previous range of 5%-9%. The higher estimate was based in part on rising truck orders and backlogs. CEO Klaus Kleinfeld said the company's transformation was in "high gear." He noted that aerospace business is a tailwind due to strong demand for commercial aircraft, and said the company is well-positioned to capture upside from recent investments. On Alcoa's Q2 earnings conference call, management said during the quarter the company witnessed revenue growth across all major end markets and the businesses continued to deliver productivity gains. They expect Q3 earnings per share to "continue to build on the strong second quarter." ATOI is expected to grow by 5%-10% over last year's third quarter due to continued share gains, stronger market conditions and productivity. Productivity gains are expected to offset cost increases in Q3. For 2014, productivity is ahead of schedule with $556M of productivity gains achieved in first half 2014 against the annual target of $850M. On September 11, Alcoa signed a multi-year supply contract with Boeing (BA) valued at over $1B. STREET RESEARCH: Street research has been overwhelmingly positive in the weeks leading up to Alcoa's Q3 earnings report. On July 9, three firms, Stifel, JP Morgan, and Argus raised their respective price targets on Alcoa. On September 30, BofA/Merrill upgraded Alcoa to Buy from Neutral with a price target of $18. The firm was more positive on the outlook for aluminum and raised Alcoa's 2015 EPS estimate to $1.05 and EBITDA to $4.1B vs. consensus of 85c and $3.8B. BofA said plant closures, better demand, and falling pension costs were catalysts. PRICE ACTION: Alcoa shares have rallied approximately 8% over the past three months, touching a 52-week high of $17.36 in September. Over the past twelve months, the stock is up about 100%. In early afternoon trading ahead of tomorrow's Q3 report, Alcoa shares are down fractionally.
10:02 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:39 EDTMMacy's Q3 revenues tracking to $6.25B vs. consensus $6.392B, says ITG Research
Subscribe for More Information
07:32 EDTICPTIntercept initiated with an Outperform at JMP Securities
Subscribe for More Information
06:03 EDTMNKDStocks with implied volatility above IV index mean; AVP MNKD
Subscribe for More Information
October 6, 2014
17:23 EDTTGTContainer Store plummets after cutting fiscal 2014 outlook
Subscribe for More Information
10:07 EDTAAAlcoa October volatility increases into Q3 and outlook
Alcoa October weekly call option implied volatility is at 63, October is at 43, November is at 32, December is at 31, January and April is at 30; compared to its 26-week average of 28 according to Track Data, suggesting large near term price movement into the expected release of Q3 results in early October 8.
10:04 EDTANFOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded to Neutral from Overweight at Piper Jaffray... Air France-KLM (AFLYY) downgraded to Neutral from Buy at Citigroup... BAE Systems (BAESY) downgraded to Hold from Buy at Societe Generale... Buffalo Wild Wings (BWLD) downgraded to Neutral from Outperform at Wedbush... Church & Dwight (CHD) downgraded to Underweight from Equal Weight at Barclays... Colgate-Palmolive (CL) downgraded to Equal Weight from Overweight at Barclays... Deckers Outdoor (DECK) downgraded to Neutral from Overweight at Piper Jaffray... Delhaize (DEG) downgraded to Hold from Buy at Deutsche Bank... Fortinet (FTNT) downgraded to Equal Weight from Overweight at Morgan Stanley... McDonald's (MCD) downgraded to Equal Weight from Overweight at Morgan Stanley... Midcoast Energy (MEP) downgraded to Neutral from Buy at UBS... Mobileye (MBLY) downgraded to Market Perform from Outperform at Raymond James... Myers Industries (MYE) downgraded to Neutral from Buy at CL King... Nationstar (NSM) downgraded to Underperform from Market Perform at Keefe Bruyette... PTC Therapeutics (PTCT) downgraded to Market Perform at Cowen... PetSmart (PETM) downgraded to Equal Weight from Overweight at Barclays... Qlik Technologies (QLIK) downgraded to Equal Weight from Overweight at Morgan Stanley... Subsea 7 (SUBCY) downgraded to Neutral from Outperform at Exane BNP Paribas... Tekmira (TKMR) downgraded to Market Perform from Outperform at ... XL Group (XL) downgraded to Market Perform from Outperform at FBR Capital... Xoom (XOOM) downgraded to Underweight from Equal-Weight at Evercore.
10:04 EDTANFOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:13 EDTSHLD, TGTMobile Marketing & Technology Magazine to hold a conference
Mobile Payments Conference is being held in Chicago on October 6-8.
06:46 EDTANFAbercrombie & Fitch downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Abercrombie & Fitch to Neutral after its channel checks indicated worsening selling conditions across Europe. Piper thinks shares could see pressure in the near-term and lowered its price target for the stock to $35 from $45. Note Abercrombie was upgraded to Buy this morning at Mizuho.
05:56 EDTANFAbercrombie & Fitch downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
05:49 EDTMNKDStocks with implied volatility movement; MNKD CLF
Stocks with implied volatility movement; MannKind (MNKD) 71, Cliffs Natural (CLF) 99 according to iVolatility.
05:37 EDTANFAbercrombie & Fitch upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use